Short Interest in Sensus Healthcare, Inc. (NASDAQ:SRTS) Rises By 107.4%

Sensus Healthcare, Inc. (NASDAQ:SRTS) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 1,210,000 shares, an increase of 107.4% from the December 31st total of 583,500 shares. Approximately 9.2% of the shares of the company are short sold. Based on an average daily volume of 203,100 shares, the days-to-cover ratio is presently 6.0 days.

Hedge Funds Weigh In On Sensus Healthcare

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Truvestments Capital LLC bought a new stake in shares of Sensus Healthcare during the 3rd quarter worth approximately $32,000. Geode Capital Management LLC increased its holdings in Sensus Healthcare by 8.5% in the 3rd quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock worth $849,000 after purchasing an additional 11,525 shares in the last quarter. XTX Topco Ltd boosted its holdings in Sensus Healthcare by 76.0% in the third quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock valued at $183,000 after acquiring an additional 13,619 shares during the last quarter. Ritholtz Wealth Management increased its stake in shares of Sensus Healthcare by 65.3% in the 4th quarter. Ritholtz Wealth Management now owns 51,261 shares of the company’s stock valued at $355,000 after acquiring an additional 20,256 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Sensus Healthcare during the second quarter valued at about $156,000. 25.30% of the stock is owned by institutional investors.

Sensus Healthcare Price Performance

NASDAQ SRTS traded down $0.22 on Wednesday, hitting $6.70. 231,987 shares of the stock were exchanged, compared to its average volume of 207,760. The company’s 50-day moving average price is $7.60 and its two-hundred day moving average price is $6.82. The company has a market capitalization of $109.81 million, a price-to-earnings ratio of 11.75 and a beta of 1.21. Sensus Healthcare has a 52-week low of $2.91 and a 52-week high of $9.33.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Maxim Group upped their price objective on Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. HC Wainwright boosted their price objective on shares of Sensus Healthcare from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, November 18th.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.